• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sera Prognostics Inc.

    4/24/26 4:11:50 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    DEFA14A 1 sera-defa14a-2026-additi.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    SERA PROGNOSTICS, INC.

     

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img103887505_0.jpg

    Your Vote Counts! SERA PROGNOSTICS, INC. 2026 Annual Meeting Vote by June 3, 2026 11:59 PM ET SERA PROGNOSTICS The Pregnancy Company® SERA PROGNOSTICS, INC. 2749 EAST PARLEYS WAY, SUITE 200 SALT LAKE CITY, UT 84109 You invested in SERA PROGNOSTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2026. Get informed before you vote View the Notice and Proxy Statement, Annual Report and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 4, 2026 9:00 a.m. Mountain Time Virtually at: www.virtualshareholdermeeting.com/SERA2026 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

    img103887505_1.jpg

    Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Directors Nominees: 01) Jeffrey T. Elliott 02) Kim Kamdar, Ph.D. 03) Sandra A.J. Lawrence 2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. NOTE: The proxy holders will vote in their discretion on any other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Board Recommends For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     


    Get the next $SERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    12/15/2025$5.00Buy
    Jefferies
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lindgardt Zhenya was granted 154,440 shares, increasing direct ownership by 21% to 892,754 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    3/13/26 6:28:36 PM ET
    $SERA
    Medical Specialities
    Health Care

    General Counsel Jackson Benjamin was granted 44,215 shares, increasing direct ownership by 39% to 158,935 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    3/13/26 6:28:19 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Medical Officer Inglis Tiffany Eul Davis was granted 17,437 shares, increasing direct ownership by 23% to 92,437 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    3/13/26 6:28:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

    SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights:Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women,

    3/18/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    Oppenheimer initiated coverage on Sera Prognostics with a new price target

    Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

    11/19/21 4:55:47 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Sera Prognostics Inc.

    DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    4/24/26 4:11:50 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Sera Prognostics Inc.

    DEF 14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    4/24/26 4:10:34 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Sera Prognostics Inc.

    144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/21/26 4:26:28 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

    Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

    5/8/25 4:40:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care